JP2001504681A - 蛋白質相互作用の阻害 - Google Patents
蛋白質相互作用の阻害Info
- Publication number
- JP2001504681A JP2001504681A JP53279897A JP53279897A JP2001504681A JP 2001504681 A JP2001504681 A JP 2001504681A JP 53279897 A JP53279897 A JP 53279897A JP 53279897 A JP53279897 A JP 53279897A JP 2001504681 A JP2001504681 A JP 2001504681A
- Authority
- JP
- Japan
- Prior art keywords
- raf
- ras
- compound
- binding
- fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Urology & Nephrology (AREA)
- Toxicology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.Rafのジンクフィンガードメインに対するRasの非イフェクターループドメイ ンの直接結合を阻害する化合物を、哺乳類に投与するかまたは哺乳類の細胞に接 触させることを含む、哺乳類において細胞の増殖を減少させる方法。 2.化合物がジンクフィンガードメイン含有ポリペプチドである、請求項1記載 の方法。 3.ポリペプチドが配列番号:1を含むものである、請求項2記載の方法。 4.ポリペプチドが配列番号:2を含むものである、請求項3記載の方法。 5.化合物が、Rafのジンクフィンガードメインに結合する脂質部分を含むもの である、請求項1記載の方法。 6.脂質部分がファルネシル部分である、請求項5記載の方法。 7.化合物がC186位でファルネシル部分を含むRasのカルボキシ末端断片を有す る、請求項6記載の方法。 8.Rafのアミノ末端Ras結合ドメインに対するRasのイフェクターループドメイ ンの直接結合を阻害する第二の異なる化合物を、哺乳類へ投与するかまたは哺乳 類の細胞に接触させることをさらに含む、請求項1記載の方法。 9.化合物が配列番号:3を含むポリペプチドである、請求項8記載の方法。 10.化合物が配列番号:4を含むポリペプチドである、請求項8記載の方法。 11.ポリペプチドが配列番号:5を含むものである、請求項10記載の方法。 12.化合物がRaf酵素活性を減少させるものである、請求項1記載の方法。 13.哺乳類がヒトである請求項1記載の方法。 14.(a)Rafのジンクフィンガードメイン含有断片を提供する段階、 (b)RasのRaf結合断片を提供する段階、 (c)Rafの該ジンクフィンガードメイン含有断片、またはRasの該Raf結合断片を 候補化合物と接触させる段階、 (d)該化合物の非存在下と比較して、該化合物の存在下で結合が減少していれ ば、該化合物がRafに対するRasの直接結合を阻害することを示す、Rafのジンク フィンガードメイン含有断片とRasの該Raf-結合断片との結合を測定する段階、 を含む、候補化合物がRafに対するRasの直接結合を阻害することができるか否か を判定する方法。 15.Rafのジンクフィンガードメイン含有断片が配列番号:1のアミノ酸配列を 含む、請求項14記載の方法。 16.Rafのジンクフィンガードメイン含有断片が、配列番号:2のアミノ酸配列 を含む、請求項15記載の方法。 17.RasのRaf結合断片がファルネシル部分を含むものである、請求項14記載の方 法。 18.ファルネシル部分がC186位である、請求項5記載の方法。 19.(a)ジンクフィンガードメインおよびキナーゼ触媒ドメインを含むRafの断 片を提供する段階、 (b)RasのRaf結合断片を提供する段階、 (c)Rafの該ジンクフィンガードメイン含有断片またはRasの該Raf結合断片を候 補化合物と接触させる段階、および (d)該化合物の非存在下と比較して、該化合物の存在下で活性が減少していれ ば、該化合物はRaf活性化を阻害することを示す、Rafの該断片のRafキナーゼ活 性を測定する段階 を含む、候補化合物がRaf活性化を阻害できるか否かを判定する方法。 20.(a)形質転換コンピテントRasをコードする実質的に純粋なDNAでトランス フェクトされた細胞を提供する段階、 (b)該細胞を候補化合物と接触させる段階、 (c)該化合物の非存在下と比較して、該化合物の存在下で細胞が減少していれ ば、該候補化合物は細胞増殖を阻害することを示す、該細胞の増殖量を測定する 段階 を含む、候補化合物が細胞増殖を阻害することができるか否かを判定する方法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1327496P | 1996-03-12 | 1996-03-12 | |
US08/814,836 US6103692A (en) | 1996-03-12 | 1997-03-11 | Inhibiting protein interactions |
US60/013,274 | 1997-03-11 | ||
US08/814,836 | 1997-03-11 | ||
PCT/US1997/003881 WO1997034146A1 (en) | 1996-03-12 | 1997-03-12 | Inhibiting protein interactions |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2001504681A true JP2001504681A (ja) | 2001-04-10 |
Family
ID=26684639
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP53279897A Ceased JP2001504681A (ja) | 1996-03-12 | 1997-03-12 | 蛋白質相互作用の阻害 |
Country Status (5)
Country | Link |
---|---|
US (1) | US6103692A (ja) |
EP (1) | EP0904539A4 (ja) |
JP (1) | JP2001504681A (ja) |
CA (1) | CA2248998A1 (ja) |
WO (1) | WO1997034146A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008513805A (ja) * | 2004-09-22 | 2008-05-01 | オデュッセイ セラ インコーポレイテッド | 新しい薬物リード及び、既知の薬物の新しい治療的用途を同定する方法 |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2334579B (en) * | 1998-02-18 | 2003-06-04 | Univ Liverpool | Treating cancer |
WO2000009684A1 (fr) | 1998-08-14 | 2000-02-24 | Japan Science And Technology Corporation | Acide nucleique capable de se lier specifiquement a une proteine cible ras |
EP1158985B1 (en) | 1999-01-13 | 2011-12-28 | Bayer HealthCare LLC | OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS |
US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
US7166475B2 (en) * | 1999-02-26 | 2007-01-23 | Cyclacel Ltd. | Compositions and methods for monitoring the modification state of a pair of polypeptides |
IL130526A0 (en) * | 1999-06-17 | 2000-06-01 | Allergene Ltd | Novel anti-allergenic agents |
US20070009544A1 (en) * | 1999-06-17 | 2007-01-11 | Ronit Eisenberg | Anti-allergic complex molecules |
IL140473A0 (en) * | 2000-12-21 | 2002-02-10 | Allergene Ltd | Anti-allergic complex molecules |
WO2002067968A2 (en) | 2001-02-21 | 2002-09-06 | Emory University | 14-3-3 binding molecules as sensitizers for anticancer therapies |
SI1478358T1 (sl) | 2002-02-11 | 2013-09-30 | Bayer Healthcare Llc | Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi |
US7498539B2 (en) * | 2002-06-18 | 2009-03-03 | Bowe Bell & Howell Company | Progressive modularity assortment system with high and low capacity bins |
UY28213A1 (es) | 2003-02-28 | 2004-09-30 | Bayer Pharmaceuticals Corp | Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos. |
DK1636585T3 (da) | 2003-05-20 | 2008-05-26 | Bayer Pharmaceuticals Corp | Diarylurinstoffer med kinasehæmmende aktivitet |
CL2004001834A1 (es) | 2003-07-23 | 2005-06-03 | Bayer Pharmaceuticals Corp | Compuesto 4-{4-[3-(4-cloro-3-trifluorometilfenil)-ureido]-3-fluorofenoxi}-piridin-2-metilamida, inhibidor de la raf, vegfr, p38 y pdgfr quinasas, sus sales; composiicon farmaceutica; combinacion farmaceutica; y su uso para tratar trastornos hiperprol |
EP1797427A4 (en) * | 2004-09-22 | 2009-04-08 | Odyssey Thera Inc | METHOD FOR IDENTIFYING NEW MEDICAMENT LEADS AND NEW THERAPEUTIC USES OF KNOWN MEDICAMENTS |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5582995A (en) * | 1993-06-11 | 1996-12-10 | The General Hospital Corporation | Methods of screening for compounds which inhibit the direct binding of Ras to Raf |
US5597719A (en) * | 1994-07-14 | 1997-01-28 | Onyx Pharmaceuticals, Inc. | Interaction of RAF-1 and 14-3-3 proteins |
-
1997
- 1997-03-11 US US08/814,836 patent/US6103692A/en not_active Expired - Fee Related
- 1997-03-12 WO PCT/US1997/003881 patent/WO1997034146A1/en not_active Application Discontinuation
- 1997-03-12 EP EP97916745A patent/EP0904539A4/en not_active Withdrawn
- 1997-03-12 CA CA002248998A patent/CA2248998A1/en not_active Abandoned
- 1997-03-12 JP JP53279897A patent/JP2001504681A/ja not_active Ceased
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008513805A (ja) * | 2004-09-22 | 2008-05-01 | オデュッセイ セラ インコーポレイテッド | 新しい薬物リード及び、既知の薬物の新しい治療的用途を同定する方法 |
JP2012154938A (ja) * | 2004-09-22 | 2012-08-16 | Odyssey Thera Inc | 新しい薬物リード及び、既知の薬物の新しい治療的用途を同定する方法 |
Also Published As
Publication number | Publication date |
---|---|
CA2248998A1 (en) | 1997-09-18 |
US6103692A (en) | 2000-08-15 |
EP0904539A4 (en) | 2002-01-30 |
WO1997034146A1 (en) | 1997-09-18 |
EP0904539A1 (en) | 1999-03-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Rittinger et al. | Structural analysis of 14-3-3 phosphopeptide complexes identifies a dual role for the nuclear export signal of 14-3-3 in ligand binding | |
US5674691A (en) | Method of screening for ligands to a receptor-type tyrosine kinase | |
Naisbitt et al. | Shank, a novel family of postsynaptic density proteins that binds to the NMDA receptor/PSD-95/GKAP complex and cortactin | |
US5763571A (en) | Inhibiting protein interactions | |
US5856445A (en) | Serine substituted mutants of BCL-XL /BCL-2 associated cell death regulator | |
US6787326B1 (en) | Interaction between the VHL tumor suppressor and hypoxia inducible factor, and assay methods relating thereto | |
JP2001504681A (ja) | 蛋白質相互作用の阻害 | |
US5821082A (en) | Anti-proliferation domain of a human Bcl-2 and DNA encoding the same | |
WO1999015657A2 (en) | 53bp2 complexes | |
US5744313A (en) | Assay employing novel protein domain which binds tyrosine phosphorylated proteins | |
WO1997034146A9 (en) | Inhibiting protein interactions | |
KR20000029469A (ko) | 신호 전달 단백질과 glgf(pdz/dhr)도메인간의 상호작용을 저해하는 화합물과 상기 화합물의 용도 | |
AU2001263952B2 (en) | Tumour suppressor and uses thereof | |
US5955259A (en) | Method for assessing modulation of potassium ion channel activity | |
US6255074B1 (en) | Abl-interactor protein | |
EP0769144B1 (en) | Assay for inhibitors of dp-1 and other dp proteins | |
MXPA05001364A (es) | Proteinas de interaccion de mk2. | |
US20020143164A1 (en) | Ras activator nucleic acid molecules, polypeptides and methods of use | |
WO1998009643A1 (en) | Modulation of apoptosis by serine phosphorylation of blc-xl/blc-2 associated cell death regulator | |
WO2004016646A2 (en) | Peptide modulators of tumour specific pyruvate kinase subtype m2 (m2-pk) | |
US20050239064A1 (en) | Methods and compositions based on protein interactions with mastermind | |
CA2325339A1 (en) | Dadd, death activator death domain protein | |
WO2008098308A1 (en) | Agents and methods for treatment of cell proliferative diseases and conditions | |
WO2002074919A2 (en) | Protein-protein interactions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20040311 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20061024 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20070122 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20070312 |
|
A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20070606 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20070717 |